XML 62 R28.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenues Revenues (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2018
Revenue from Contract with Customer [Abstract] |
Revenues by product | Revenues by product are summarized as follows:
| For the Three Months Ended June 30,
(In millions) | 2018 |  | 2017
| United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis: |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 825.8 |  |  | $ | 261.0 |  |  | $ | 1,086.8 |  |  | $ | 875.0 |  |  | $ | 235.6 |  |  | $ | 1,110.6 |
Interferon* | 444.7 |  |  | 180.8 |  |  | 625.5 |  |  | 501.7 |  |  | 188.9 |  |  | 690.6 |
TYSABRI | 265.5 |  |  | 201.7 |  |  | 467.2 |  |  | 289.4 |  |  | 206.6 |  |  | 496.0 |
FAMPYRA | — |  |  | 23.0 |  |  | 23.0 |  |  | — |  |  | 22.6 |  |  | 22.6 |
ZINBRYTA | — |  |  | — |  |  | — |  |  | — |  |  | 16.1 |  |  | 16.1 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | 205.9 |  |  | 216.8 |  |  | 422.7 |  |  | 194.8 |  |  | 8.1 |  |  | 202.9 |
Other Product Revenues: |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 5.5 |  |  | 5.5 |  |  | — |  |  | 10.3 |  |  | 10.3 |
BENEPALI | — |  |  | 115.6 |  |  | 115.6 |  |  | — |  |  | 88.7 |  |  | 88.7 |
FLIXABI | — |  |  | 11.2 |  |  | 11.2 |  |  | — |  |  | 1.9 |  |  | 1.9 |
Total product revenues | $ | 1,741.9 |  |  | $ | 1,015.6 |  |  | $ | 2,757.5 |  |  | $ | 1,860.9 |  |  | $ | 778.8 |  |  | $ | 2,639.7 |
*Interferon includes AVONEX and PLEGRIDY.
| For the Six Months Ended June 30,
(In millions) | 2018 |  | 2017
| United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis: |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 1,554.7 |  |  | $ | 519.0 |  |  | $ | 2,073.7 |  |  | $ | 1,626.1 |  |  | $ | 442.7 |  |  | $ | 2,068.8 |
Interferon* | 816.0 |  |  | 359.8 |  |  | 1,175.8 |  |  | 966.5 |  |  | 372.4 |  |  | 1,338.9 |
TYSABRI | 515.2 |  |  | 414.1 |  |  | 929.3 |  |  | 594.9 |  |  | 446.1 |  |  | 1,041.0 |
FAMPYRA | — |  |  | 47.4 |  |  | 47.4 |  |  | — |  |  | 43.1 |  |  | 43.1 |
ZINBRYTA | — |  |  | 1.4 |  |  | 1.4 |  |  | — |  |  | 26.8 |  |  | 26.8 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | 393.9 |  |  | 392.7 |  |  | 786.6 |  |  | 241.2 |  |  | 9.1 |  |  | 250.3 |
Hemophilia: |  |  |  |  |  |  |  |  |  |  |
ELOCTATE | — |  |  | — |  |  | — |  |  | 42.2 |  |  | 6.2 |  |  | 48.4 |
ALPROLIX | — |  |  | — |  |  | — |  |  | 21.0 |  |  | 5.0 |  |  | 26.0 |
Other Product Revenues: |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 12.5 |  |  | 12.5 |  |  | — |  |  | 20.0 |  |  | 20.0 |
BENEPALI | — |  |  | 236.5 |  |  | 236.5 |  |  | — |  |  | 154.0 |  |  | 154.0 |
FLIXABI | — |  |  | 17.8 |  |  | 17.8 |  |  | — |  |  | 2.5 |  |  | 2.5 |
Total product revenues | $ | 3,279.8 |  |  | $ | 2,001.2 |  |  | $ | 5,281.0 |  |  | $ | 3,491.9 |  |  | $ | 1,527.9 |  |  | $ | 5,019.8 |
*Interferon includes AVONEX and PLEGRIDY.
Analysis of change In reserves | An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions) | Discounts |  | Contractual Adjustments |  | Returns |  | Total
Balance, as of December 31, 2017 | $ | 109.6 |  |  | $ | 606.0 |  |  | $ | 46.0 |  |  | $ | 761.6 |
Current provisions relating to sales in current year | 333.2 |  |  | 1,288.0 |  |  | 11.4 |  |  | 1,632.6 |
Adjustments relating to prior years | (0.3 | ) |  | 7.4 |  |  | 2.6 |  |  | 9.7 |
Payments/credits relating to sales in current year | (222.3 | ) |  | (731.9 | ) |  | — |  |  | (954.2 | )
Payments/credits relating to sales in prior years | (101.0 | ) |  | (469.6 | ) |  | (13.5 | ) |  | (584.1 | )
Balance, as of June 30, 2018 | $ | 119.2 |  |  | $ | 699.9 |  |  | $ | 46.5 |  |  | $ | 865.6 |
Total reserves included in consolidated balance sheets | The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:
(In millions) | As of June 30, 2018 |  | As of December 31, 2017
Reduction of accounts receivable | $ | 162.8 |  |  | $ | 189.6 |
Component of accrued expenses and other | 702.8 |  |  | 572.0 |
Total reserves | $ | 865.6 |  |  | $ | 761.6 |
Revenues from anti-CD20 therapeutic programs | Revenues from anti-CD20 therapeutic programs are summarized as follows:
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2018 |  | 2017 |  | 2018 |  | 2017
Biogen’s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA | $ | 359.0 |  |  | $ | 347.5 |  |  | $ | 708.6 |  |  | $ | 671.0 |
Other revenues from anti-CD20 therapeutic programs | 131.4 |  |  | 49.6 |  |  | 225.0 |  |  | 66.7 |
Total revenues from anti-CD20 therapeutic programs | $ | 490.4 |  |  | $ | 397.1 |  |  | $ | 933.6 |  |  | $ | 737.7 |
Other revenues | Other revenues are summarized as follows:
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2018 |  | 2017 |  | 2018 |  | 2017
Revenues from collaborative and other relationships: |  |  |  |  |  |  |
AbbVie | $ | (2.5 | ) |  | $ | (3.9 | ) |  | $ | (7.2 | ) |  | $ | (9.8 | )
Samsung Bioepis and other | 14.7 |  |  | 12.9 |  |  | 32.6 |  |  | 25.1 |
Other royalty and corporate revenues: |  |  |  |  |  |  |
Royalty | 17.3 |  |  | 11.8 |  |  | 27.9 |  |  | 37.3 |
Other corporate | 79.1 |  |  | 20.8 |  |  | 219.7 |  |  | 79.0 |
Total other revenues | $ | 108.6 |  |  | $ | 41.6 |  |  | $ | 273.0 |  |  | $ | 131.6 |

X
- Definition Analysis of amount of and change in product revenue reserves. + References No definition available. + Details
Name: | biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other revenues [Table Text Block] + References No definition available. + Details
Name: | biib_OtherrevenuesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of total product revenue reserves included in consolidated balance sheets. + References No definition available. + Details
Name: | biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration